자궁근종 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약제 클래스별, 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030F)
Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Type, By End User, By Region & Competition, 2020-2030F
세계의 자궁근종 치료제 시장 규모는 2024년에 48억 5,000만 달러에 달하며, 2030년까지 CAGR 4.40%로 안정된 성장을 기록할 것으로 예측됩니다.
| 시장 개요 |
| 예측 기간 |
2026-2030 |
| 시장 규모 : 2024년 |
48억 5,000만 달러 |
| 시장 규모 : 2030년 |
62억 9,000만 달러 |
| CAGR : 2025-2030년 |
4.40% |
| 급성장 부문 |
점막하 근종 |
| 최대 시장 |
북미 |
시장 확대는 전 세계 자궁근종 유병률 증가, 비수술적 치료 옵션에 대한 선호도 증가, 제약 연구 발전, 의료 서비스 접근성 향상 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 평활근종이라고도 불리는 자궁근종은 가임기 여성에게 영향을 미치는 가장 흔한 양성 종양 중 하나이며, 월경 과다 출혈, 골반통, 불임 합병증을 동반하는 경우가 많습니다.
치료에 대한 인식이 높아지고, 진단 방법이 개선되고, 치료 접근성이 확대됨에 따라 약리학적 치료의 채택이 가속화되고 있습니다. 특히 성선자극호르몬 방출 호르몬(GnRH) 길항제, 프로게스틴 기반 요법, 비호르몬 대체요법의 사용 증가가 두드러지며, 이는 수술적 치료보다 비침습적 치료법을 선호하는 환자들의 광범위한 변화를 반영합니다. 특히 자궁근종 발병률이 급증하고 치료 접근성이 개선되고 있는 지역에서는 지속적인 약물 혁신, 규제 당국의 승인률 증가, 보험 적용 범위 확대가 시장 전망을 밝게 하고 있습니다.
주요 시장 성장 촉진요인
자궁근종의 유병률 상승
주요 시장이 해결해야 할 과제
한정된 장기 유효성 및 안전성 데이터
주요 시장 동향
병용요법의 출현
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 임상시험 분석
제6장 세계의 자궁근종 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 약제 클래스별(고나도트로핀 방출 호르몬(GNRH) 작용제, 고나도트로핀 방출 호르몬(GNRH) 길항제, 프로게스틴 방출 자궁내 피임기구(IUD) 및 피임약, 비호르몬성 의약품, 기타)
- 유형별(장막하 근종, 벽내 근종, 점막하 근종, 유경성 근종)
- 최종사용자별(병원 약국, 소매 약국, 기타)
- 지역별
- 기업별(2024)
- 제품 시장 맵
제7장 북미의 자궁근종 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 북미 : 국가별 분석
제8장 유럽의 자궁근종 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 유럽 : 국가별 분석
제9장 아시아태평양의 자궁근종 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 아시아태평양 : 국가별 분석
제10장 남미의 자궁근종 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 남미 : 국가별 분석
제11장 중동 및 아프리카의 자궁근종 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제12장 시장 역학
제13장 시장 동향과 발전
제14장 정책과 규제 상황
제15장 Porter's Five Forces 분석
- 업계내 경쟁
- 신규 참여의 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제16장 경쟁 구도
- Myovant Sciences Ltd
- Pfizer Inc
- Abbvie Inc
- Ferring BV
- AstraZeneca
- Bayer AG
- Amring Pharmaceuticals Inc
- Watson Pharma Pvt Ltd
제17장 전략적 제안
제18장 조사회사 소개·면책사항
KSA
Global Uterine Fibroid Treatment Drugs Market was valued at USD 4.85 billion in 2024 and is projected to register steady growth at a compound annual growth rate (CAGR) of 4.40% through 2030.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 4.85 Billion |
| Market Size 2030 | USD 6.29 Billion |
| CAGR 2025-2030 | 4.40% |
| Fastest Growing Segment | Submucosal Fibroids |
| Largest Market | North America |
Market expansion is being driven by several key factors, including the rising global prevalence of uterine fibroids, increasing preference for non-surgical treatment options, advancements in pharmaceutical research, and greater accessibility to healthcare services. Uterine fibroids, also referred to as leiomyomas, are among the most common benign tumors affecting women of reproductive age and are often associated with heavy menstrual bleeding, pelvic pain, and fertility complications.
Growing awareness, improved diagnostic practices, and expanded access to treatment have accelerated the adoption of pharmacological therapies. This is particularly evident in the increasing use of gonadotropin-releasing hormone (GnRH) antagonists, progestin-based regimens, and non-hormonal alternatives, reflecting a broader shift in patient preference toward non-invasive therapies over surgical procedures. Ongoing drug innovations, higher regulatory approval rates, and expanding insurance coverage continue to support the market's positive outlook, especially in regions witnessing a surge in fibroid incidence and improved access to care.
Key Market Drivers
Rising Prevalence of Uterine Fibroids
The increasing global prevalence of uterine fibroids is a primary growth driver for the market. These benign pelvic tumors, although non-cancerous, are widespread among women of reproductive age. Due to their frequently asymptomatic nature, actual prevalence is likely underreported. Studies indicate a wide prevalence range from 4.5% to 68.6%, influenced by variables such as diagnostic methods, population demographics, and healthcare availability.
As the number of diagnosed cases continues to rise, so does the demand for effective pharmacological treatment. Factors such as late pregnancies, hormonal imbalances, and a global increase in obesity contribute significantly to the growing incidence of uterine fibroids. For instance, in 2022, one in every eight individuals globally was affected by obesity. Since 1990, obesity rates have more than doubled in adults and quadrupled in adolescents, with 2.5 billion adults classified as overweight, including 890 million with obesity. These health trends further amplify the burden of uterine fibroids and underscore the demand for scalable, non-invasive treatment solutions.
Key Market Challenges
Limited Long-Term Efficacy and Safety Data
While pharmaceutical treatments for uterine fibroids have demonstrated notable effectiveness in managing symptoms, concerns remain regarding their long-term safety and efficacy. Many clinical studies feature relatively short follow-up periods, limiting insights into extended use and sustained outcomes. To ensure continued patient trust and optimize treatment strategies, robust long-term clinical data is essential. Such data will help address safety concerns, inform regulatory decisions, and guide healthcare providers in making evidence-based therapeutic choices.
Key Market Trends
Emergence of Combination Therapies
The market is witnessing a growing interest in combination therapy approaches, integrating uterine fibroid drugs with minimally invasive procedures or complementary hormonal treatments. These integrated solutions offer the potential for enhanced symptom relief, improved patient outcomes, and a more personalized treatment experience.
Combination therapies are especially promising for patients with varying fibroid types, sizes, or symptoms, allowing for tailored care strategies that target fibroids through multiple mechanisms. This approach not only improves therapeutic efficacy but also reduces the likelihood of recurrence, positioning combination treatment as a compelling solution in the evolving landscape of uterine fibroid care.
Key Market Players
- Myovant Sciences Ltd
- Pfizer Inc
- Abbvie Inc
- Ferring BV
- AstraZeneca
- Bayer AG
- Amring Pharmaceuticals Inc
- Watson Pharma Pvt Ltd
Report Scope:
In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Uterine Fibroid Treatment Drugs Market, By Drug Class:
- Gonadotropin-Releasing Hormone (Gnrh) Agonists
- Gonadotropin-Releasing Hormone (Gnrh) Antagonists
- Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
- Non-Hormonal Medications
- Others
Uterine Fibroid Treatment Drugs Market, By Type:
- Subserosal Fibroids
- Intramural Fibroids
- Submucosal Fibroids
- Pedunculated Fibroids
Uterine Fibroid Treatment Drugs Market, By End User:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Uterine Fibroid Treatment Drugs Market, By region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Competitive Landscape
Uterine Fibroid Treatment Drugs Market.
Available Customizations:
Global Uterine Fibroid Treatment Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
- 5.1. Ongoing Clinical Trials
- 5.2. Completed Clinical Trials
- 5.3. Terminated Clinical Trials
- 5.4. Breakdown of Pipeline, By Development Phase
- 5.5. Breakdown of Pipeline, By Status
- 5.6. Breakdown of Pipeline, By Study Application
- 5.7. Breakdown of Pipeline, By Region
- 5.8. Clinical Trials Heat Map
6. Global Uterine Fibroid Treatment Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
- 6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
- 6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
- 6.2.4. By Region
- 6.2.5. By Company (2024)
- 6.3. Product Market Map
7. North America Uterine Fibroid Treatment Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Type
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Class
- 7.3.1.2.2. By Type
- 7.3.1.2.3. By End User
- 7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Class
- 7.3.2.2.2. By Type
- 7.3.2.2.3. By End User
- 7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Class
- 7.3.3.2.2. By Type
- 7.3.3.2.3. By End User
8. Europe Uterine Fibroid Treatment Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Type
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Europe: Country Analysis
- 8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Class
- 8.3.1.2.2. By Type
- 8.3.1.2.3. By End User
- 8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Class
- 8.3.2.2.2. By Type
- 8.3.2.2.3. By End User
- 8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Class
- 8.3.3.2.2. By Type
- 8.3.3.2.3. By End User
- 8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Class
- 8.3.4.2.2. By Type
- 8.3.4.2.3. By End User
- 8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Class
- 8.3.5.2.2. By Type
- 8.3.5.2.3. By End User
9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Type
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Class
- 9.3.1.2.2. By Type
- 9.3.1.2.3. By End User
- 9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Class
- 9.3.2.2.2. By Type
- 9.3.2.2.3. By End User
- 9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Class
- 9.3.3.2.2. By Type
- 9.3.3.2.3. By End User
- 9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
- 9.3.4.1. Market Size & Forecast
- 9.3.4.2. Market Share & Forecast
- 9.3.4.2.1. By Drug Class
- 9.3.4.2.2. By Type
- 9.3.4.2.3. By End User
- 9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
- 9.3.5.1. Market Size & Forecast
- 9.3.5.2. Market Share & Forecast
- 9.3.5.2.1. By Drug Class
- 9.3.5.2.2. By Type
- 9.3.5.2.3. By End User
10. South America Uterine Fibroid Treatment Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Type
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Class
- 10.3.1.2.2. By Type
- 10.3.1.2.3. By End User
- 10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Class
- 10.3.2.2.2. By Type
- 10.3.2.2.3. By End User
- 10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Class
- 10.3.3.2.2. By Type
- 10.3.3.2.3. By End User
11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook
- 11.1. Market Size & Forecast
- 11.2. Market Share & Forecast
- 11.2.1. By Drug Class
- 11.2.2. By Type
- 11.2.3. By End User
- 11.2.4. By Country
- 11.3. MEA: Country Analysis
- 11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Drug Class
- 11.3.1.2.2. By Type
- 11.3.1.2.3. By End User
- 11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Drug Class
- 11.3.2.2.2. By Type
- 11.3.2.2.3. By End User
- 11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Drug Class
- 11.3.3.2.2. By Type
- 11.3.3.2.3. By End User
- 11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
- 11.3.4.1. Market Size & Forecast
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Drug Class
- 11.3.4.2.2. By Type
- 11.3.4.2.3. By End User
12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
13. Market Trends & Developments
- 13.1. Recent Developments
- 13.2. Product Launches
- 13.3. Mergers & Acquisitions
14. Policy & Regulatory Landscape
15. Porter's Five Forces Analysis
- 15.1. Competition in the Industry
- 15.2. Potential of New Entrants
- 15.3. Power of Suppliers
- 15.4. Power of Customers
- 15.5. Threat of Substitute Product
16. Competitive Landscape
- 16.1. Myovant Sciences Ltd
- 16.1.1. Business Overview
- 16.1.2. Product & Service Offerings
- 16.1.3. Recent Developments
- 16.1.4. Financials (If Listed)
- 16.1.5. Key Personnel
- 16.1.6. SWOT Analysis
- 16.2. Pfizer Inc
- 16.3. Abbvie Inc
- 16.4. Ferring BV
- 16.5. AstraZeneca
- 16.6. Bayer AG
- 16.7. Amring Pharmaceuticals Inc
- 16.8. Watson Pharma Pvt Ltd
17. Strategic Recommendations
18. About Us & Disclaimer
